<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240502061001&amp;fc=20230708114047&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240502061001&amp;fc=20230708114047&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 02 May 2024 10:10:02 +0000</lastbuilddate>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>The Rise of 2 Interacting Subspecialties in Cardiology: Cardiometabolic Diseases and the Microcirculation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38692831/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7;83(18):1821-1823. doi: 10.1016/j.jacc.2024.03.397.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38692831/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38692831</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.397>10.1016/j.jacc.2024.03.397</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38692831</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Viviany R Taqueti</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Rise of 2 Interacting Subspecialties in Cardiology: Cardiometabolic Diseases and the Microcirculation</dc:title>
<dc:identifier>pmid:38692831</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.397</dc:identifier>
</item>
<item>
<title>Management of Severe Mitral Regurgitation in Patients With Acute Myocardial Infarction: JACC Focus Seminar 2/5</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38692830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>Severe acute mitral regurgitation after myocardial infarction includes partial and complete papillary muscle rupture or functional mitral regurgitation. Although its incidence is &lt;1%, mitral regurgitation after acute myocardial infarction frequently causes hemodynamic instability, pulmonary edema, and cardiogenic shock. Medical management has the worst prognosis, and mortality has not changed in decades. Surgery represents the gold standard, but it is associated with high rates of morbidity and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7;83(18):1799-1817. doi: 10.1016/j.jacc.2023.09.840.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Severe acute mitral regurgitation after myocardial infarction includes partial and complete papillary muscle rupture or functional mitral regurgitation. Although its incidence is &lt;1%, mitral regurgitation after acute myocardial infarction frequently causes hemodynamic instability, pulmonary edema, and cardiogenic shock. Medical management has the worst prognosis, and mortality has not changed in decades. Surgery represents the gold standard, but it is associated with high rates of morbidity and mortality. Recently, transcatheter interventions have opened a new door for management that may improve survival. Mechanical circulatory support restores vital organ perfusion and offers the opportunity for a steadier surgical repair. This review focuses on the diagnosis and the interventional management, both surgical and transcatheter, with a glance on future perspectives to enhance patient management and eventually decrease mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38692830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38692830</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.840>10.1016/j.jacc.2023.09.840</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38692830</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Rodrigo Estévez-Loureiro</dc:creator>
<dc:creator>Roberto Lorusso</dc:creator>
<dc:creator>Maurizio Taramasso</dc:creator>
<dc:creator>Gianluca Torregrossa</dc:creator>
<dc:creator>Annapoorna Kini</dc:creator>
<dc:creator>Pedro R Moreno</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Management of Severe Mitral Regurgitation in Patients With Acute Myocardial Infarction: JACC Focus Seminar 2/5</dc:title>
<dc:identifier>pmid:38692830</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.840</dc:identifier>
</item>
<item>
<title>Right Ventricular Myocardial Infarction-A Tale of Two Ventricles: JACC Focus Seminar 1/5</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38692829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>Right ventricular infarction (RVI) complicates 50% of cases of acute inferior ST-segment elevation myocardial infarction, and is associated with high in-hospital morbidity and mortality. Ischemic right ventricular (RV) systolic dysfunction decreases left ventricular preload delivery, resulting in low-output hypotension with clear lungs, and disproportionate right heart failure. RV systolic performance is generated by left ventricular contractile contributions mediated by the septum. Augmented...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7;83(18):1779-1798. doi: 10.1016/j.jacc.2023.09.839.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Right ventricular infarction (RVI) complicates 50% of cases of acute inferior ST-segment elevation myocardial infarction, and is associated with high in-hospital morbidity and mortality. Ischemic right ventricular (RV) systolic dysfunction decreases left ventricular preload delivery, resulting in low-output hypotension with clear lungs, and disproportionate right heart failure. RV systolic performance is generated by left ventricular contractile contributions mediated by the septum. Augmented right atrial contraction optimizes RV performance, whereas very proximal occlusions induce right atrial ischemia exacerbating hemodynamic compromise. RVI is associated with vagal mediated bradyarrhythmias, both during acute occlusion and abruptly with reperfusion. The ischemic dilated RV is also prone to malignant ventricular arrhythmias. Nevertheless, RV is remarkably resistant to infarction. Reperfusion facilitates RV recovery, even after prolonged occlusion and in patients with severe shock. However, in some cases hemodynamic compromise persists, necessitating pharmacological and mechanical circulatory support with dedicated RV assist devices as a "bridge to recovery."</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38692829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38692829</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.839>10.1016/j.jacc.2023.09.839</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38692829</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>James A Goldstein</dc:creator>
<dc:creator>Stamatios Lerakis</dc:creator>
<dc:creator>Pedro R Moreno</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Right Ventricular Myocardial Infarction-A Tale of Two Ventricles: JACC Focus Seminar 1/5</dc:title>
<dc:identifier>pmid:38692829</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.839</dc:identifier>
</item>
<item>
<title>Can Plaque Imaging Improve Risk Assessment Among Individuals With Elevated Lp(a)?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38692828/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7;83(18):1756-1759. doi: 10.1016/j.jacc.2024.03.386.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38692828/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38692828</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.386>10.1016/j.jacc.2024.03.386</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38692828</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Ron Blankstein</dc:creator>
<dc:creator>Arthur Shiyovich</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Can Plaque Imaging Improve Risk Assessment Among Individuals With Elevated Lp(a)?</dc:title>
<dc:identifier>pmid:38692828</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.386</dc:identifier>
</item>
<item>
<title>Association of Lipoprotein(a) Levels With Myocardial Infarction in Patients With Low-Attenuation Plaque</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38692827/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Elevated Lp(a) augmented the risk of MI during 8 years of follow-up, especially in patients with LAP identified by CCTA. The presence of LAP could reinforce the relationship between Lp(a) and future MI occurrence.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7;83(18):1743-1755. doi: 10.1016/j.jacc.2024.03.367.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lipoprotein(a) (Lp[a]) is associated with an increased risk of myocardial infarction (MI). However, the mechanism underlying this association has yet to be fully elucidated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This multicenter study aimed to investigate whether association between Lp(a) and MI risk is reinforced by the presence of low-attenuation plaque (LAP) identified by coronary computed tomography angiography (CCTA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In a derivation cohort, a total of 5,607 patients with stable chest pain suspected of coronary artery disease who underwent CCTA and Lp(a) measurement were prospectively enrolled. In validation cohort, 1,122 patients were retrospectively collected during the same period. High Lp(a) was defined as Lp(a) ≥50 mg/dL. The primary endpoint was a composite of time to fatal or nonfatal MI. Associations were estimated using multivariable Cox proportional hazard models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During a median follow-up of 8.2 years (Q1-Q3: 7.2-9.3 years), the elevated Lp(a) levels were associated with MI risk (adjusted HR [aHR]: 1.91; 95% CI: 1.46-2.49; P &lt; 0.001). There was a significant interaction between Lp(a) and LAP (P<sub>interaction</sub> &lt;0.001) in relation to MI risk. When stratified by the presence or absence of LAP, Lp(a) was associated with MI in patients with LAP (aHR: 3.03; 95% CI: 1.92-4.76; P &lt; 0.001). Mediation analysis revealed that LAP mediated 73.3% (P &lt; 0.001) for the relationship between Lp(a) and MI. The principal findings remained unchanged in the validation cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Elevated Lp(a) augmented the risk of MI during 8 years of follow-up, especially in patients with LAP identified by CCTA. The presence of LAP could reinforce the relationship between Lp(a) and future MI occurrence.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38692827/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38692827</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.367>10.1016/j.jacc.2024.03.367</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38692827</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Meng-Meng Yu</dc:creator>
<dc:creator>Ming-Liang Wang</dc:creator>
<dc:creator>Jin-Jin Wang</dc:creator>
<dc:creator>Bo-Li Lin</dc:creator>
<dc:creator>Xin Zhao</dc:creator>
<dc:creator>Xin-Wei Tao</dc:creator>
<dc:creator>Yin-Yin Chen</dc:creator>
<dc:creator>Peng-Yang Li</dc:creator>
<dc:creator>Jing-Kun Zhang</dc:creator>
<dc:creator>Jun-Bo Ge</dc:creator>
<dc:creator>Hang Jin</dc:creator>
<dc:creator>Meng-Su Zeng</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association of Lipoprotein(a) Levels With Myocardial Infarction in Patients With Low-Attenuation Plaque</dc:title>
<dc:identifier>pmid:38692827</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.367</dc:identifier>
</item>
<item>
<title>Clonal Hematopoiesis Among Patients With Asymptomatic Carotid Stenosis Compounds Risk of Cardiovascular Death</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38692826/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7;83(18):1728-1730. doi: 10.1016/j.jacc.2024.03.389.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38692826/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38692826</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.389>10.1016/j.jacc.2024.03.389</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38692826</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Tiffany R Bellomo</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clonal Hematopoiesis Among Patients With Asymptomatic Carotid Stenosis Compounds Risk of Cardiovascular Death</dc:title>
<dc:identifier>pmid:38692826</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.389</dc:identifier>
</item>
<item>
<title>Combined Effects of Clonal Hematopoiesis and Carotid Stenosis on Cardiovascular Mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38692825/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: CH status in combination with the extent of carotid atherosclerosis jointly predict long-term mortality. Determination of CH can provide additional prognostic information in patients with asymptomatic carotid atherosclerosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7;83(18):1717-1727. doi: 10.1016/j.jacc.2024.02.043.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The expansion of hematopoietic stem cells caused by acquired somatic mutations (clonal hematopoiesis [CH]) is a novel cardiovascular risk factor. The prognostic value of CH in patients with carotid atherosclerosis remains to be evaluated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study assessed the prognostic significance of CH in patients with atherosclerosis as detected by ultrasound of the carotid artery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We applied deep sequencing of selected genomic regions within the genes DNMT3A, TET2, ASXL1, and JAK2 to screen for CH in 968 prospectively collected patients with asymptomatic carotid atherosclerosis evaluated by duplex sonography.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We detected clonal markers at variant allele frequency ≥2% in 133 (13.7%) of 968 patients (median age 69.2 years), with increasing prevalence at advanced age. Multivariate analyses including age and established cardiovascular risk factors revealed overall presence of CH to be significantly associated with increased risk of cardiovascular death (HR: 1.50; 95% CI: 1.12-2.00; P = 0.007), reflected also at the single gene level. The effect of CH was more pronounced in older patients and independent of the patients' inflammatory status as measured by high-sensitivity C-reactive protein. Simultaneous assessment of CH and degree of carotid stenosis revealed combined effects on cardiovascular mortality, depicted by a superior risk for patients with >;50% stenosis and concomitant CH (adjusted HR: 1.60; 95% CI: 1.08-2.38; P = 0.020).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CH status in combination with the extent of carotid atherosclerosis jointly predict long-term mortality. Determination of CH can provide additional prognostic information in patients with asymptomatic carotid atherosclerosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38692825/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38692825</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.043>10.1016/j.jacc.2024.02.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38692825</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Roland Jäger</dc:creator>
<dc:creator>Matthias Hoke</dc:creator>
<dc:creator>Florian J Mayer</dc:creator>
<dc:creator>Stefanie Boden</dc:creator>
<dc:creator>Cornelia Englisch</dc:creator>
<dc:creator>Cihan Ay</dc:creator>
<dc:creator>Robert Kralovics</dc:creator>
<dc:creator>Christoph J Binder</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Combined Effects of Clonal Hematopoiesis and Carotid Stenosis on Cardiovascular Mortality</dc:title>
<dc:identifier>pmid:38692825</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.043</dc:identifier>
</item>
<item>
<title>Deep Learning-Based Assessment of Built Environment From Satellite Images and Cardiometabolic Disease Prevalence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38691380/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this cross-sectional study, a significant portion of cardiometabolic disease prevalence was associated with GSI-based built environment using convolutional neural networks.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 May 1. doi: 10.1001/jamacardio.2024.0749. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Built environment plays an important role in development of cardiovascular disease. Large scale, pragmatic evaluation of built environment has been limited owing to scarce data and inconsistent data quality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the association between image-based built environment and the prevalence of cardiometabolic disease in urban cities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used features extracted from Google satellite images (GSI) to measure the built environment and link them with prevalence of cardiometabolic disease. Convolutional neural networks, light gradient-boosting machines, and activation maps were used to assess the association with health outcomes and identify feature associations with coronary heart disease (CHD), stroke, and chronic kidney disease (CKD). The study obtained aerial images from GSI covering census tracts in 7 cities (Cleveland, Ohio; Fremont, California; Kansas City, Missouri; Detroit, Michigan; Bellevue, Washington; Brownsville, Texas; and Denver, Colorado). The study used census tract-level data from the US Centers for Disease Control and Prevention's 500 Cities project. The data were originally collected from the Behavioral Risk Factor Surveillance System that surveyed people 18 years and older across the country. Analyses were conducted from February to December 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: GSI images of built environment and cardiometabolic disease prevalence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Census tract-level estimated prevalence of CHD, stroke, and CKD based on image-based built environment features.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study obtained 31 786 aerial images from GSI covering 789 census tracts. Built environment features extracted from GSI using machine learning were associated with prevalence of CHD (R2 = 0.60), stroke (R2 = 0.65), and CKD (R2 = 0.64). The model performed better at distinguishing differences between cardiometabolic prevalence between cities than within cities (eg, highest within-city R2 = 0.39 vs between-city R2 = 0.64 for CKD). Addition of GSI features both outperformed and improved the model that only included age, sex, race, income, education, and composite indices for social determinants of health (R2 = 0.83 vs R2 = 0.76 for CHD; P &lt;.001). Activation maps from the features revealed certain health-related built environment such as roads, highways, and railroads and recreational facilities such as amusement parks, arenas, and baseball parks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this cross-sectional study, a significant portion of cardiometabolic disease prevalence was associated with GSI-based built environment using convolutional neural networks.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38691380/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38691380</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0749>10.1001/jamacardio.2024.0749</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38691380</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhuo Chen</dc:creator>
<dc:creator>Jean-Eudes Dazard</dc:creator>
<dc:creator>Yassin Khalifa</dc:creator>
<dc:creator>Issam Motairek</dc:creator>
<dc:creator>Catherine Kreatsoulas</dc:creator>
<dc:creator>Sanjay Rajagopalan</dc:creator>
<dc:creator>Sadeer Al-Kindi</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Deep Learning-Based Assessment of Built Environment From Satellite Images and Cardiometabolic Disease Prevalence</dc:title>
<dc:identifier>pmid:38691380</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0749</dc:identifier>
</item>
<item>
<title>Wide Complex Tachycardia in a Middle-Aged Woman With Diarrhea</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38691373/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 May 1. doi: 10.1001/jamacardio.2024.0744. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38691373/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38691373</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0744>10.1001/jamacardio.2024.0744</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38691373</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew G Peters</dc:creator>
<dc:creator>Nachiket Apte</dc:creator>
<dc:creator>Dinesh K Kalra</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Wide Complex Tachycardia in a Middle-Aged Woman With Diarrhea</dc:title>
<dc:identifier>pmid:38691373</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0744</dc:identifier>
</item>
<item>
<title>Error in Figure 3</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38691370/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 May 1. doi: 10.1001/jamacardio.2024.1006. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38691370/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38691370</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1006>10.1001/jamacardio.2024.1006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38691370</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-01</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Figure 3</dc:title>
<dc:identifier>pmid:38691370</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1006</dc:identifier>
</item>
<item>
<title>Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38690659/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among patients with functional MR associated with HF, ertugliflozin significantly improved LV global longitudinal strain and left atrial remodeling, and reduced functional MR. Sodium-glucose cotransporter 2 inhibitors may be considered for patients with functional MR.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 1. doi: 10.1161/CIRCULATIONAHA.124.069144. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The morbidity and mortality rates of patients with heart failure (HF) and functional mitral regurgitation (MR) remain substantial despite guideline-directed medical therapy for HF. We evaluated the efficacy of ertugliflozin for reduction of functional MR associated with HF with mild to moderately reduced ejection fraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The EFFORT trial (Ertugliflozin for Functional Mitral Regurgitation) was a multicenter, double-blind, randomized trial to examine the hypothesis that the sodium-glucose cotransporter 2 inhibitor ertugliflozin is effective for improving MR in patients with HF with New York Heart Association functional class II or III, 35%≤ejection fraction&lt;50%, and effective regurgitant orifice area of chronic functional MR >;0.1 cm<sup>2</sup> on baseline echocardiography. We randomly assigned 128 patients to receive either ertugliflozin or placebo in addition to guideline-directed medical therapy for HF. The primary end point was change in effective regurgitant orifice area of functional MR from baseline to the 12-month follow-up. Secondary end points included changes in regurgitant volume, left ventricular (LV) volume indices, left atrial volume index, LV global longitudinal strain, and NT-proBNP (N-terminal pro-B-type natriuretic peptide).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The treatment groups were generally well-balanced with regard to baseline characteristics: mean age, 66±11 years; 61% men; 13% diabetes; 51% atrial fibrillation; 43% use of angiotensin receptor-neprilysin inhibitor; ejection fraction, 42±8%; and effective regurgitant orifice area, 0.20±0.12 cm<sup>2</sup>. The decrease in effective regurgitant orifice area was significantly greater in the ertugliflozin group than in the placebo group (-0.05±0.06 versus 0.03±0.12 cm<sup>2</sup>; <i>P</i>&lt;0.001). Compared with placebo, ertugliflozin significantly reduced regurgitant volume by 11.2 mL (95% CI, -16.1 to -6.3; <i>P</i>=0.009), left atrial volume index by 6.0 mL/m<sup>2</sup> (95% CI, -12.16 to 0.15; <i>P</i>=0.005), and LV global longitudinal strain by 1.44% (95% CI, -2.42% to -0.46%; <i>P</i>=0.004). There were no significant between-group differences regarding changes in LV volume indices, ejection fraction, or NT-proBNP levels. Serious adverse events occurred in one patient (1.6%) in the ertugliflozin group and 6 (9.2%) in the placebo group (<i>P</i>=0.12).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients with functional MR associated with HF, ertugliflozin significantly improved LV global longitudinal strain and left atrial remodeling, and reduced functional MR. Sodium-glucose cotransporter 2 inhibitors may be considered for patients with functional MR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04231331.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38690659/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38690659</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069144>10.1161/CIRCULATIONAHA.124.069144</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38690659</guid>
<pubDate>Wed, 01 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Duk-Hyun Kang</dc:creator>
<dc:creator>Sung-Ji Park</dc:creator>
<dc:creator>Sung-Hee Shin</dc:creator>
<dc:creator>In-Chang Hwang</dc:creator>
<dc:creator>Yeonyee Elizabeth Yoon</dc:creator>
<dc:creator>Hyung-Kwan Kim</dc:creator>
<dc:creator>Mijin Kim</dc:creator>
<dc:creator>Min-Seok Kim</dc:creator>
<dc:creator>Sung-Cheol Yun</dc:creator>
<dc:creator>Jong-Min Song</dc:creator>
<dc:creator>Seok-Min Kang</dc:creator>
<dc:date>2024-05-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial</dc:title>
<dc:identifier>pmid:38690659</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069144</dc:identifier>
</item>
<item>
<title>Caring for patients with lower extremity artery disease: going beyond stents and bypass grafts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38687682/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 30:ehae195. doi: 10.1093/eurheartj/ehae195. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38687682/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38687682</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae195>10.1093/eurheartj/ehae195</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38687682</guid>
<pubDate>Tue, 30 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Victor Aboyans</dc:creator>
<dc:creator>Marco De Carlo</dc:creator>
<dc:date>2024-04-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Caring for patients with lower extremity artery disease: going beyond stents and bypass grafts</dc:title>
<dc:identifier>pmid:38687682</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae195</dc:identifier>
</item>
<item>
<title>Spatiotemporal ATF3 Expression Determines VSMC Fate in Abdominal Aortic Aneurysm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38686580/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our results demonstrate a previously unrecognized role of ATF3 in AAA development and progression, and ATF3 may serve as a novel therapeutic and prognostic marker for AAA.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 30. doi: 10.1161/CIRCRESAHA.124.324323. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Abdominal aortic aneurysm (AAA) is a catastrophic disease with little effective therapy, likely due to the limited understanding of the mechanisms underlying AAA development and progression. Activating transcription factor (ATF) 3 has been increasingly recognized as a key regulator of cardiovascular diseases. However, the role of ATF3 (activating transcription factor 3) in AAA development and progression remains elusive.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Genome-wide RNA sequencing analysis was performed on the aorta isolated from saline or Ang II (angiotensin II)-induced AAA mice, and ATF3 was identified as the potential key gene for AAA development. To examine the role of ATF3 in AAA development, vascular smooth muscle cell-specific ATF3 knockdown or overexpressed mice by recombinant adenoassociated virus serotype 9 vectors carrying ATF3, or shRNA-ATF3 with SM22α (smooth muscle protein 22-α) promoter were used in Ang II (angiotensin II)-induced AAA mice. In human and murine vascular smooth muscle cells, gain or loss of function experiments were performed to investigate the role of ATF3 in vascular smooth muscle cell proliferation and apoptosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In both Ang II-induced AAA mice and patients with AAA, the expression of ATF3 was reduced in aneurysm tissues but increased in aortic lesion tissues. The deficiency of ATF3 in vascular smooth muscle cell promoted AAA formation in Ang II-induced AAA mice. PDGFRB (platelet-derived growth factor receptor β) was identified as the target of ATF3, which mediated vascular smooth muscle cell proliferation in response to TNF-alpha (tumor necrosis factor-α) at the early stage of AAA. ATF3 suppressed the mitochondria-dependent apoptosis at the advanced stage by upregulating its direct target BCL2. Our chromatin immunoprecipitation results also demonstrated that the recruitment of NFκB1 and P300/BAF/H3K27ac complex to the ATF3 promoter induces ATF3 transcription via enhancer activation. NFKB1 inhibitor (andrographolide) inhibits the expression of ATF3 by blocking the recruiters NFKB1 and ATF3-enhancer to the ATF3-promoter region, ultimately leading to AAA development.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results demonstrate a previously unrecognized role of ATF3 in AAA development and progression, and ATF3 may serve as a novel therapeutic and prognostic marker for AAA.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38686580/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38686580</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324323>10.1161/CIRCRESAHA.124.324323</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38686580</guid>
<pubDate>Tue, 30 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Ying Wen</dc:creator>
<dc:creator>Yingying Liu</dc:creator>
<dc:creator>Qiang Li</dc:creator>
<dc:creator>Jinlin Tan</dc:creator>
<dc:creator>Xing Fu</dc:creator>
<dc:creator>Yiwen Liang</dc:creator>
<dc:creator>Yonghua Tuo</dc:creator>
<dc:creator>Luhao Liu</dc:creator>
<dc:creator>Xueqiong Zhou</dc:creator>
<dc:creator>Dongkai LiuFu</dc:creator>
<dc:creator>Xuejiao Fan</dc:creator>
<dc:creator>Chaofei Chen</dc:creator>
<dc:creator>Zheng Chen</dc:creator>
<dc:creator>Zhouping Wang</dc:creator>
<dc:creator>Shunyang Fan</dc:creator>
<dc:creator>Renjing Liu</dc:creator>
<dc:creator>Lei Pan</dc:creator>
<dc:creator>Yuan Zhang</dc:creator>
<dc:creator>Wai Ho Tang</dc:creator>
<dc:date>2024-04-30</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Spatiotemporal ATF3 Expression Determines VSMC Fate in Abdominal Aortic Aneurysm</dc:title>
<dc:identifier>pmid:38686580</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324323</dc:identifier>
</item>
<item>
<title>Rectifying METTL4-Mediated N&lt;sup>;6&lt;/sup>;-Methyladenine Excess in Mitochondrial DNA Alleviates Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38686562/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings identify a pivotal role of cardiomyocyte mtDNA 6mA and the corresponding methyltransferase, METTL4, in the pathogenesis of mitochondrial dysfunction and HF. Targeted suppression of METTL4 to rectify mtDNA 6mA excess emerges as a promising strategy for developing mitochondria-focused HF interventions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30. doi: 10.1161/CIRCULATIONAHA.123.068358. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Myocardial mitochondrial dysfunction underpins the pathogenesis of heart failure (HF), yet therapeutic options to restore myocardial mitochondrial function are scarce. Epigenetic modifications of mitochondrial DNA (mtDNA), such as methylation, play a pivotal role in modulating mitochondrial homeostasis. However, their involvement in HF remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Experimental HF models were established through continuous angiotensin II and phenylephrine (AngII/PE) infusion or prolonged myocardial ischemia/reperfusion injury. The landscape of N<sup>6</sup>-methyladenine (6mA) methylation within failing cardiomyocyte mtDNA was characterized using high-resolution mass spectrometry and methylated DNA immunoprecipitation sequencing. A tamoxifen-inducible cardiomyocyte-specific <i>Mettl4</i> knockout mouse model and adeno-associated virus vectors designed for cardiomyocyte-targeted manipulation of METTL4 (methyltransferase-like protein 4) expression were used to ascertain the role of mtDNA 6mA and its methyltransferase METTL4 in HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: METTL4 was predominantly localized within adult cardiomyocyte mitochondria. 6mA modifications were significantly more abundant in mtDNA than in nuclear DNA. Postnatal cardiomyocyte maturation presented with a reduction in 6mA levels within mtDNA, coinciding with a decrease in METTL4 expression. However, an increase in both mtDNA 6mA level and METTL4 expression was observed in failing adult cardiomyocytes, suggesting a shift toward a neonatal-like state. METTL4 preferentially targeted mtDNA promoter regions, which resulted in interference with transcription initiation complex assembly, mtDNA transcriptional stalling, and ultimately mitochondrial dysfunction. Amplifying cardiomyocyte mtDNA 6mA through METTL4 overexpression led to spontaneous mitochondrial dysfunction and HF phenotypes. The transcription factor p53 was identified as a direct regulator of METTL4 transcription in response to HF-provoking stress, thereby revealing a stress-responsive mechanism that controls METTL4 expression and mtDNA 6mA. Cardiomyocyte-specific deletion of the <i>Mettl4</i> gene eliminated mtDNA 6mA excess, preserved mitochondrial function, and mitigated the development of HF upon continuous infusion of AngII/PE. In addition, specific silencing of METTL4 in cardiomyocytes restored mitochondrial function and offered therapeutic relief in mice with preexisting HF, irrespective of whether the condition was induced by AngII/PE infusion or myocardial ischemia/reperfusion injury.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings identify a pivotal role of cardiomyocyte mtDNA 6mA and the corresponding methyltransferase, METTL4, in the pathogenesis of mitochondrial dysfunction and HF. Targeted suppression of METTL4 to rectify mtDNA 6mA excess emerges as a promising strategy for developing mitochondria-focused HF interventions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38686562/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38686562</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068358>10.1161/CIRCULATIONAHA.123.068358</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38686562</guid>
<pubDate>Tue, 30 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Fuyang Zhang</dc:creator>
<dc:creator>Ling Zhang</dc:creator>
<dc:creator>Guangyu Hu</dc:creator>
<dc:creator>Xiyao Chen</dc:creator>
<dc:creator>Hui Liu</dc:creator>
<dc:creator>Congye Li</dc:creator>
<dc:creator>Xiong Guo</dc:creator>
<dc:creator>Chong Huang</dc:creator>
<dc:creator>Fangfang Sun</dc:creator>
<dc:creator>Tongzheng Li</dc:creator>
<dc:creator>Zhe Cui</dc:creator>
<dc:creator>Yongzhen Guo</dc:creator>
<dc:creator>Wenjun Yan</dc:creator>
<dc:creator>Yunlong Xia</dc:creator>
<dc:creator>Zhiyuan Liu</dc:creator>
<dc:creator>Zhen Lin</dc:creator>
<dc:creator>Weixun Duan</dc:creator>
<dc:creator>Linhe Lu</dc:creator>
<dc:creator>Xinyi Wang</dc:creator>
<dc:creator>Zhengyang Wang</dc:creator>
<dc:creator>Shan Wang</dc:creator>
<dc:creator>Ling Tao</dc:creator>
<dc:date>2024-04-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Rectifying METTL4-Mediated N&lt;sup>;6&lt;/sup>;-Methyladenine Excess in Mitochondrial DNA Alleviates Heart Failure</dc:title>
<dc:identifier>pmid:38686562</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068358</dc:identifier>
</item>
<item>
<title>Atherosclerosis Is a Smooth Muscle Cell-Driven Tumor-Like Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38686559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings demonstrate that atherosclerosis is an SMC-driven tumor-like disease, advancing our understanding of its pathogenesis and opening prospects for innovative precision molecular strategies aimed at preventing and treating atherosclerotic cardiovascular disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30. doi: 10.1161/CIRCULATIONAHA.123.067587. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Atherosclerosis, a leading cause of cardiovascular disease, involves the pathological activation of various cell types, including immunocytes (eg, macrophages and T cells), smooth muscle cells (SMCs), and endothelial cells. Accumulating evidence suggests that transition of SMCs to other cell types, known as phenotypic switching, plays a central role in atherosclerosis development and complications. However, the characteristics of SMC-derived cells and the underlying mechanisms of SMC transition in disease pathogenesis remain poorly understood. Our objective is to characterize tumor cell-like behaviors of SMC-derived cells in atherosclerosis, with the ultimate goal of developing interventions targeting SMC transition for the prevention and treatment of atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used SMC lineage tracing mice and human tissues and applied a range of methods, including molecular, cellular, histological, computational, human genetics, and pharmacological approaches, to investigate the features of SMC-derived cells in atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: SMC-derived cells in mouse and human atherosclerosis exhibit multiple tumor cell-like characteristics, including genomic instability, evasion of senescence, hyperproliferation, resistance to cell death, invasiveness, and activation of comprehensive cancer-associated gene regulatory networks. Specific expression of the oncogenic mutant <i>Kras</i><sup><i>G12D</i></sup> in SMCs accelerates phenotypic switching and exacerbates atherosclerosis. Furthermore, we provide proof of concept that niraparib, an anticancer drug targeting DNA damage repair, attenuates atherosclerosis progression and induces regression of lesions in advanced disease in mouse models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings demonstrate that atherosclerosis is an SMC-driven tumor-like disease, advancing our understanding of its pathogenesis and opening prospects for innovative precision molecular strategies aimed at preventing and treating atherosclerotic cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38686559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38686559</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067587>10.1161/CIRCULATIONAHA.123.067587</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38686559</guid>
<pubDate>Tue, 30 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Huize Pan</dc:creator>
<dc:creator>Sebastian E Ho</dc:creator>
<dc:creator>Chenyi Xue</dc:creator>
<dc:creator>Jian Cui</dc:creator>
<dc:creator>Quinian S Johanson</dc:creator>
<dc:creator>Nadja Sachs</dc:creator>
<dc:creator>Leila S Ross</dc:creator>
<dc:creator>Fang Li</dc:creator>
<dc:creator>Robert A Solomon</dc:creator>
<dc:creator>E Sander Connolly</dc:creator>
<dc:creator>Virendra I Patel</dc:creator>
<dc:creator>Lars Maegdefessel</dc:creator>
<dc:creator>Hanrui Zhang</dc:creator>
<dc:creator>Muredach P Reilly</dc:creator>
<dc:date>2024-04-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Atherosclerosis Is a Smooth Muscle Cell-Driven Tumor-Like Disease</dc:title>
<dc:identifier>pmid:38686559</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067587</dc:identifier>
</item>
<item>
<title>Atherosclerotic plaque-specific methylation biomarkers in plasma cell-free DNA of female and male patients with coronary artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38685672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 30:ehae156. doi: 10.1093/eurheartj/ehae156. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38685672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38685672</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae156>10.1093/eurheartj/ehae156</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38685672</guid>
<pubDate>Tue, 30 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Ernest Diez Benavente</dc:creator>
<dc:creator>Tim R Sakkers</dc:creator>
<dc:creator>Pim van der Harst</dc:creator>
<dc:creator>Hester M den Ruijter</dc:creator>
<dc:date>2024-04-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atherosclerotic plaque-specific methylation biomarkers in plasma cell-free DNA of female and male patients with coronary artery disease</dc:title>
<dc:identifier>pmid:38685672</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae156</dc:identifier>
</item>
<item>
<title>Embolic strokes of undetermined source: a clinical consensus statement of the ESC Council on Stroke, the European Association of Cardiovascular Imaging and the European Heart Rhythm Association of the ESC</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38685132/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>One in six ischaemic stroke patients has an embolic stroke of undetermined source (ESUS), defined as a stroke with unclear aetiology despite recommended diagnostic evaluation. The overall cardiovascular risk of ESUS is high and it is important to optimize strategies to prevent recurrent stroke and other cardiovascular events. The aim of clinicians when confronted with a patient not only with ESUS but also with any other medical condition of unclear aetiology is to identify the actual cause...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 30:ehae150. doi: 10.1093/eurheartj/ehae150. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">One in six ischaemic stroke patients has an embolic stroke of undetermined source (ESUS), defined as a stroke with unclear aetiology despite recommended diagnostic evaluation. The overall cardiovascular risk of ESUS is high and it is important to optimize strategies to prevent recurrent stroke and other cardiovascular events. The aim of clinicians when confronted with a patient not only with ESUS but also with any other medical condition of unclear aetiology is to identify the actual cause amongst a list of potential differential diagnoses, in order to optimize secondary prevention. However, specifically in ESUS, this may be challenging as multiple potential thromboembolic sources frequently coexist. Also, it can be delusively reassuring because despite the implementation of specific treatments for the individual pathology presumed to be the actual thromboembolic source, patients can still be vulnerable to stroke and other cardiovascular events caused by other pathologies already identified during the index diagnostic evaluation but whose thromboembolic potential was underestimated. Therefore, rather than trying to presume which particular mechanism is the actual embolic source in an ESUS patient, it is important to assess the overall thromboembolic risk of the patient through synthesis of the individual risks linked to all pathologies present, regardless if presumed causally associated or not. In this paper, a multi-disciplinary panel of clinicians/researchers from various backgrounds of expertise and specialties (cardiology, internal medicine, neurology, radiology and vascular surgery) proposes a comprehensive multi-dimensional assessment of the overall thromboembolic risk in ESUS patients through the composition of individual risks associated with all prevalent pathologies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38685132/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38685132</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae150>10.1093/eurheartj/ehae150</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38685132</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>George Ntaios</dc:creator>
<dc:creator>Helmut Baumgartner</dc:creator>
<dc:creator>Wolfram Doehner</dc:creator>
<dc:creator>Erwan Donal</dc:creator>
<dc:creator>Thor Edvardsen</dc:creator>
<dc:creator>Jeff S Healey</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Hooman Kamel</dc:creator>
<dc:creator>Scott E Kasner</dc:creator>
<dc:creator>Eleni Korompoki</dc:creator>
<dc:creator>Babak B Navi</dc:creator>
<dc:creator>Christian Pristipino</dc:creator>
<dc:creator>Luca Saba</dc:creator>
<dc:creator>Renate B Schnabel</dc:creator>
<dc:creator>Emma Svennberg</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Embolic strokes of undetermined source: a clinical consensus statement of the ESC Council on Stroke, the European Association of Cardiovascular Imaging and the European Heart Rhythm Association of the ESC</dc:title>
<dc:identifier>pmid:38685132</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae150</dc:identifier>
</item>
<item>
<title>Unraveling the Unsolved Mysteries of the Athletic Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38683901/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30;149(18):1416-1418. doi: 10.1161/CIRCULATIONAHA.124.064534. Epub 2024 Apr 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38683901/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38683901</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.064534>10.1161/CIRCULATIONAHA.124.064534</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38683901</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>William K Cornwell</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Unraveling the Unsolved Mysteries of the Athletic Heart</dc:title>
<dc:identifier>pmid:38683901</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.064534</dc:identifier>
</item>
<item>
<title>Empowering Valvular Heart Disease Research With Stem Cell-Derived Valve Cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38683900/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30;149(18):1457-1460. doi: 10.1161/CIRCULATIONAHA.124.068656. Epub 2024 Apr 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38683900/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38683900</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068656>10.1161/CIRCULATIONAHA.124.068656</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38683900</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Mengcheng Shen</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Empowering Valvular Heart Disease Research With Stem Cell-Derived Valve Cells</dc:title>
<dc:identifier>pmid:38683900</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068656</dc:identifier>
</item>
<item>
<title>Global Rounds: Cardiovascular Care in Australia and New Zealand</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38683899/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30;149(18):1402-1404. doi: 10.1161/CIRCULATIONAHA.123.064271. Epub 2024 Apr 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38683899/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38683899</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064271>10.1161/CIRCULATIONAHA.123.064271</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38683899</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Sarah Zaman</dc:creator>
<dc:creator>Nicola C Edwards</dc:creator>
<dc:creator>Derek P Chew</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Global Rounds: Cardiovascular Care in Australia and New Zealand</dc:title>
<dc:identifier>pmid:38683899</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064271</dc:identifier>
</item>
<item>
<title>Peripheral Oxygenation and Pulmonary Hemodynamics in Individuals With Fontan Circulation During 24-Hour High-Altitude Exposure Simulation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38683898/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240502061001&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 30;149(18):1466-1468. doi: 10.1161/CIRCULATIONAHA.123.067601. Epub 2024 Apr 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38683898/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240502061001&v=2.18.0.post9+e462414">38683898</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067601>10.1161/CIRCULATIONAHA.123.067601</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38683898</guid>
<pubDate>Mon, 29 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Nicole Müller</dc:creator>
<dc:creator>Julian Alexander Härtel</dc:creator>
<dc:creator>Jan Schmitz</dc:creator>
<dc:creator>Ute Baur</dc:creator>
<dc:creator>Melanie von der Wiesche</dc:creator>
<dc:creator>Iris Rieger</dc:creator>
<dc:creator>Darius Gerlach</dc:creator>
<dc:creator>Jon von Stritzky</dc:creator>
<dc:creator>Anja Bach</dc:creator>
<dc:creator>Christopher Hart</dc:creator>
<dc:creator>Janina Bros</dc:creator>
<dc:creator>Benedikt Seeger</dc:creator>
<dc:creator>Emily Zollmann</dc:creator>
<dc:creator>Marijke Grau</dc:creator>
<dc:creator>Boris Dragutinovic</dc:creator>
<dc:creator>Laura-Maria de Boni</dc:creator>
<dc:creator>Jan-Niklas Hönemann</dc:creator>
<dc:creator>Wilhelm Bloch</dc:creator>
<dc:creator>Daniel Aeschbach</dc:creator>
<dc:creator>Eva-Maria Elmenhorst</dc:creator>
<dc:creator>Ulrike Herberg</dc:creator>
<dc:creator>Alena Hess</dc:creator>
<dc:creator>Moritz Schumann</dc:creator>
<dc:creator>Tobias Kratz</dc:creator>
<dc:creator>Jens Jordan</dc:creator>
<dc:creator>Johannes Breuer</dc:creator>
<dc:creator>Jens Tank</dc:creator>
<dc:date>2024-04-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Peripheral Oxygenation and Pulmonary Hemodynamics in Individuals With Fontan Circulation During 24-Hour High-Altitude Exposure Simulation</dc:title>
<dc:identifier>pmid:38683898</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067601</dc:identifier>
</item>





























</channel>
</rss>